-- Health care stocks were leaning lower premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) declining by 0.4% and the iShares Biotechnology ETF (IBB) down 0.5%.
Biogen (BIIB) has agreed to acquire TJ Biopharma's rights to the felzartamab antibody in the Greater China Region under a definitive agreement, the companies said. Biogen shares were up more than 1% pre-bell.
AstraZeneca (AZN) said its pivotal phase 3 study of tozorakimab demonstrated a "significant" reduction in the annual rate of moderate-to-severe chronic obstructive pulmonary disease, or COPD, exacerbations in trial participants. Shares of AstraZeneca were down more than 1% premarket.
ANI Pharmaceuticals (ANIP) stock was up more than 1% after the company said it has received US Food and Drug Administration approval and launched Pimozide Tablets in 1 mg and 2 mg doses, the generic version of Orap, with 180-day Competitive Generic Therapy exclusivity.